Ata Serdar, Köşeci Tolga, Benli Burcu Arslan, Bayhan Ahmet Ziya, Kesen Oğuzhan, Solmaz Ali Alper, Demir Hakan, Çil Timuçin, Bozkurt Duman Berna
Department of Medical Oncology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey.
Department of Medical Oncology, Faculty of Medicine, Çukurova University, Adana, Turkey.
Medicine (Baltimore). 2025 May 2;104(18):e42261. doi: 10.1097/MD.0000000000042261.
Patients with metastatic malignant melanoma have a survival rate of less than one year. Nivolumab, a monoclonal antibody against programmed cell death 1 (PD-1) receptor, has improved survival in patients without BRAF mutations. The HALP score, calculated from hemoglobin, albumin, lymphocyte, and platelet levels, provides information about a patient immune and nutritional status. High HALP scores have been associated with a better prognosis in various cancers. This study aimed to investigate the effect of high HALP scores on response to nivolumab treatment in patients with metastatic malignant melanoma. A retrospective study was conducted on 44 patients with metastatic malignant melanoma treated with nivolumab at Adana City Training and Research Hospital between 2014 and 2021. Patients who received dabrafenib-trametinib before nivolumab treatment were excluded. The HALP scores were calculated using laboratory parameters before the first nivolumab treatment. Statistical analyses were performed using SPSS version 25.0. The study included 22 female and 22 male patients with a mean age of 61.4 ± 15.6 years. Of the patients, 10 (27.2%) had a positive BRAF mutation, whereas 34 (77.3%) did not. The HALP score cutoff value was determined as 30.1. Patients with high HALP scores had significantly longer progression-free survival (PFS) and overall survival (OS) compared to those with low HALP scores (PFS: median 5.8 vs 3.1 months, P = .041; OS: median 54.9 vs 14.4 months, P = .005). In this study, we found that high HALP scores were significantly associated with longer PFS and OS in metastatic malignant melanoma patients receiving nivolumab treatment. HALP score was associated with both PFS and OS in patients with metastatic malignant melanoma treated with nivolumab. This immuno-nutritional parameter may be useful in various cancers; however, further prospective studies with larger patient cohorts are needed for clinical application.
转移性恶性黑色素瘤患者的生存率不到一年。纳武单抗是一种抗程序性细胞死亡1（PD-1）受体的单克隆抗体，它提高了无BRAF突变患者的生存率。根据血红蛋白、白蛋白、淋巴细胞和血小板水平计算得出的HALP评分，可提供有关患者免疫和营养状况的信息。高HALP评分与多种癌症的较好预后相关。本研究旨在调查高HALP评分对转移性恶性黑色素瘤患者接受纳武单抗治疗反应的影响。对2014年至2021年间在阿达纳市培训和研究医院接受纳武单抗治疗的44例转移性恶性黑色素瘤患者进行了一项回顾性研究。排除在纳武单抗治疗前接受达拉非尼-曲美替尼治疗的患者。使用首次纳武单抗治疗前的实验室参数计算HALP评分。使用SPSS 25.0版进行统计分析。该研究纳入了22名女性和22名男性患者，平均年龄为61.4±15.6岁。在这些患者中，10例（27.2%）有BRAF阳性突变，而34例（77.3%）没有。HALP评分临界值确定为30.1。与低HALP评分的患者相比，高HALP评分的患者无进展生存期（PFS）和总生存期（OS）明显更长（PFS：中位数5.8个月对3.1个月，P = 0.041；OS：中位数54.9个月对14.4个月，P = 0.005）。在本研究中，我们发现高HALP评分与接受纳武单抗治疗的转移性恶性黑色素瘤患者更长的PFS和OS显著相关。HALP评分与接受纳武单抗治疗的转移性恶性黑色素瘤患者的PFS和OS均相关。这个免疫营养参数可能对多种癌症有用；然而，临床应用还需要对更大患者队列进行进一步的前瞻性研究。
